Joseph Keegan - Stereotaxis Independent Director
| STXS Stock | USD 2.38 0.18 7.03% |
Director
Dr. Joseph D. Keegan Ph.D. is Independent Director of Stereotaxis Inc. He served as the president chief executive officer and a director of ForteBio Inc. a VC funded life sciences company from 2007 until February 2012. He currently serves as a director of Seahorse Bioscience Inc. Response Biomedical Corporationration as chairman of the board of Labcyte Corporation and as a director and chairman of the board of the Analytical and Life Science Systems Association. From 1998 to 2007 Dr. Keegan was president chief executive officer and a director of Molecular Devices Corporationrationration. From 1992 to 1998 he held several senior management positions with Becton Dickinson and Company including president of Worldwide Tissue Culture and vice president and general manager of Worldwide Flow Cytometry. Prior to that he held a number of positions with Leica Inc. General Electric Company and Hewlett Packard Company. He previously served as a director of Alpha Innotech Corporationration BioImagene Corporation Essen Instruments and Upstate Biotechnology. He also serves on the board of directors of the San Francisco Opera since 2011.
| Age | 60 |
| Tenure | 13 years |
| Professional Marks | Ph.D |
| Address | 710 North Tucker Boulevard, Saint Louis, MO, United States, 63101 |
| Phone | 314 678 6100 |
| Web | https://www.stereotaxis.com |
Stereotaxis Management Efficiency
The company has return on total asset (ROA) of (0.2864) % which means that it has lost $0.2864 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7693) %, meaning that it created substantial loss on money invested by shareholders. Stereotaxis' management efficiency ratios could be used to measure how well Stereotaxis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to gain to -0.72 in 2024. At this time, Stereotaxis' Other Current Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 38.5 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 4.7 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Dennis Meteny | AngioDynamics | 64 | |
| Argil Wheelock | EDAP TMS SA | 66 | |
| Mark Lanning | AtriCure | 63 | |
| Pierre Beysson | EDAP TMS SA | N/A | |
| Emad Rizk | Accuray Incorporated | 52 | |
| Kevin Gould | AngioDynamics | 63 | |
| Gregory Barrett | Cutera Inc | 64 | |
| Joseph Whitters | Cutera Inc | 60 | |
| Regina Groves | AtriCure | 59 | |
| Jack Goldstein | Accuray Incorporated | 70 | |
| Daniel Plants | Cutera Inc | 57 | |
| Katherine Zanotti | Cutera Inc | 63 | |
| Jan Reed | AngioDynamics | 58 | |
| Joseph Whitters | Accuray Incorporated | 60 | |
| Scott Drake | AtriCure | 50 | |
| Robert White | AtriCure | 56 | |
| Robert Weiss | Accuray Incorporated | 70 | |
| Mark Collar | AtriCure | 65 | |
| Steven Laporte | AngioDynamics | 66 | |
| Timothy OShea | Cutera Inc | 65 | |
| Beverly Huss | Accuray Incorporated | 57 | |
Management Performance
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.29 |
Stereotaxis Leadership Team
Elected by the shareholders, the Stereotaxis' board of directors comprises two types of representatives: Stereotaxis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stereotaxis. The board's role is to monitor Stereotaxis' management team and ensure that shareholders' interests are well served. Stereotaxis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stereotaxis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Duane DeSisto, Director | ||
| Ross Levin, Director | ||
| Paul Brathwaite, Vice President - Research & Development | ||
| Laura Garth, General Secretary | ||
| Arun Menawat, Director | ||
| CAIA CFA, CEO Chairman | ||
| Joseph Keegan, Independent Director | ||
| John Platt, Director Software | ||
| Joseph Kiani, Director | ||
| Fred Middleton, Independent Director | ||
| Keith Galloway, Vice Operations | ||
| Guy Judkowski, Equity Manager | ||
| David Fischel, Director | ||
| Brian Kidd, RD Devel | ||
| Euan Thomson, Independent Director | ||
| Eric Prystowsky, Independent Director | ||
| Karen Duros, Sr. VP, General Counsel and Secretary | ||
| Frank Cheng, Sr. VP of Marketing and Bus. Devel. | ||
| Susan Lanigan, Executive Vice President General Counsel | ||
| David Giffin, VP of HR | ||
| Martin Stammer, CFO and Principal Accounting Officer | ||
| Nathan Kastelein, RD Concepts | ||
| Robert Messey, Independent Director | ||
| William Mills, Chairman of the Board, CEO | ||
| Nathan Fischel, Director | ||
| David Benfer, Independent Director | ||
| Kimberly Peery, CFO Secretary |
Stereotaxis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stereotaxis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.77 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (1.16) % | ||||
| Current Valuation | 201.49 M | ||||
| Shares Outstanding | 82.13 M | ||||
| Shares Owned By Insiders | 15.87 % | ||||
| Shares Owned By Institutions | 47.50 % | ||||
| Number Of Shares Shorted | 925.39 K | ||||
| Price To Earning | 21.61 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Stereotaxis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Stereotaxis' short interest history, or implied volatility extrapolated from Stereotaxis options trading.
Currently Active Assets on Macroaxis
When determining whether Stereotaxis is a strong investment it is important to analyze Stereotaxis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Stereotaxis' future performance. For an informed investment choice regarding Stereotaxis Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stereotaxis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. For more information on how to buy Stereotaxis Stock please use our How to Invest in Stereotaxis guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Stereotaxis Stock analysis
When running Stereotaxis' price analysis, check to measure Stereotaxis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stereotaxis is operating at the current time. Most of Stereotaxis' value examination focuses on studying past and present price action to predict the probability of Stereotaxis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stereotaxis' price. Additionally, you may evaluate how the addition of Stereotaxis to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Stereotaxis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stereotaxis. If investors know Stereotaxis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stereotaxis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share 0.332 | Quarterly Revenue Growth (0.38) | Return On Assets (0.29) | Return On Equity (0.77) |
The market value of Stereotaxis is measured differently than its book value, which is the value of Stereotaxis that is recorded on the company's balance sheet. Investors also form their own opinion of Stereotaxis' value that differs from its market value or its book value, called intrinsic value, which is Stereotaxis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stereotaxis' market value can be influenced by many factors that don't directly affect Stereotaxis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stereotaxis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stereotaxis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stereotaxis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.